Pricing
  1. JP-listed companies
  2. Linical Co., Ltd.
  3. Financials
  4. Capital expenditures

Linical Co., Ltd.【JP:2183】

Market cap
¥6.9B
P/E ratio
-3.7x
Linical helps pharmaceutical companies develop and launch new drugs by providing clinical trial services, post-market safety monitoring, and drug discovery support.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCapital expenditures (Million JPY)YoY (%)
Mar 31, 2025-3-90.28%
Mar 31, 2024-30+150.94%
Mar 31, 2023-12-73.77%
Mar 31, 2022-45+101.83%
Mar 31, 2021-22-80.67%
Mar 31, 2020-116+172.20%
Mar 31, 2019-42-30.41%
Mar 31, 2018-61+116.67%
Mar 31, 2017-28-26.58%
Mar 31, 2016-38+176.82%
Mar 31, 2015-14

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)